1.56

4.29% -0.07

Alzamend Neuro Inc (ALZN)

Overview News Price History Financials Why ALZN Down? Discussions Forecast Stock Split

Alzamend Neuro Inc stock is traded at $1.56, with a volume of 236.16K. It is down -4.29% in the last 24 hours and up +18.18% over the past month. Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Previous Close:

$1.63

Open:

$1.57

24h Volume:

236.16K

Relative Volume:

1.75

Market Cap:

$7.47M

Revenue:

Net Income/Loss:

$-7.04M

P/E Ratio:

-0.3563

EPS:

-4.3784

Net Cash Flow:

$-6.17M

1W Performance:

+0.65%

1M Performance:

+18.18%

6M Performance:

-20.81%

1Y Performance:

-33.62%

1-Day Range:

$1.49

$1.5984

1-Week Range:

$1.4807

$1.67

52-Week Range:

$0.84

$2.68

Alzamend Neuro Inc Stock (ALZN) Company Profile

Name

Alzamend Neuro Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

844-722-6333

Address

480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA

Employee

Twitter

Next Earnings Date

2026-09-09

Latest SEC Filings

ALZN's Discussions on Twitter

Compare ALZN vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALZN Alzamend Neuro Inc	1.56	7.81M	0	-7.04M	-6.17M	-4.3784
VRTX Vertex Pharmaceuticals Inc	548.05	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	834.04	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,039.78	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.13	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.46	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-01-21	Initiated	Ascendiant Capital Markets	Buy

Alzamend Neuro Inc Stock (ALZN) Latest News

Aug 20, 2026

Alzamend Neuro (ALZN) files amended insider trading report - Stock Titan

Aug 20, 2026

Alzamend’s lithium treatment data accepted for neuroscience meeting - Investing.com

Aug 20, 2026

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC - PR Newswire

Aug 20, 2026

Aug 19, 2026

Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga

Aug 19, 2026

Aug 18, 2026

Alzamend (ALZN) Results at a Glance: Profit Per Share Clears Its Benchmark on the Day; Post-Earnings Trading - vinanet.vn

Aug 18, 2026

Alzamend to present lithium imaging data at Barcelona workshop By Investing.com - Investing.com Canada

Aug 18, 2026

Alzamend to present lithium imaging data at Barcelona workshop - Investing.com South Africa

Aug 18, 2026

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain - Investing News Network

Aug 18, 2026

Aug 13, 2026

Alzamend Neuro (ALZN) Advances 2.1% as Shares Hold Above $1.39 SupportDiagonal Spread Trade - vinanet.vn

Aug 13, 2026

Aug 08, 2026

ALZN Q2 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline Remains CentralEarnings Preview - vinanet.vn

Aug 08, 2026

Aug 06, 2026

Alzamend Neuro (ALZN) Drops 3.5% to $1.38 as Shares Approach Key SupportBreak of Structure - dars.gov.et

Aug 06, 2026

Aug 04, 2026

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending - marketscreener.com

Aug 04, 2026

Alzamend Neuro secures $7.5M in initial funding tranche - Investing.com

Aug 04, 2026

Alzamend Neuro Secures $25 Million Preferred Stock Financing - TipRanks

Aug 04, 2026

Aug 03, 2026

Alzamend Neuro Secures Up to $25 Million Series D Preferred Financing; $7.5 Million Funded - TradingView

Aug 03, 2026

Aug 01, 2026

ALZN Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.47 Highlights Cost DisciplineEstimate Revision Count - Vinanet

Aug 01, 2026

Jul 28, 2026

Alzamend Neuro’s New Lithium Study Puts AL001 in the Bipolar Disorder Spotlight - TipRanks

Jul 28, 2026

Jul 27, 2026

ALZN|Alzamend Neuro Inc|Price:1.350|Chg%:+0.040 - TradingKey

Jul 27, 2026

Alzamend Neuro Inc reports results for the quarter ended April 30Earnings Summary - TradingView

Jul 27, 2026

TradingKey - TradingKey

Jul 27, 2026